請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/679
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 程蘊菁(Yen-Ching Chen) | |
dc.contributor.author | Ming-Lun Han | en |
dc.contributor.author | 韓明倫 | zh_TW |
dc.date.accessioned | 2021-05-11T04:56:14Z | - |
dc.date.available | 2019-08-27 | |
dc.date.available | 2021-05-11T04:56:14Z | - |
dc.date.copyright | 2019-08-27 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-08-11 | |
dc.identifier.citation | 1. 2016 Alzheimer's disease facts and figures. Alzheimers Dement, 2016. 12(4): p. 459-509.
2. Sun, Y., H.J. Lee, S.C. Yang, et al., A nationwide survey of mild cognitive impairment and dementia, including very mild dementia, in Taiwan. PLoS One, 2014. 9(6): p. e100303. 3. Gelinas, D.S., K. DaSilva, D. Fenili, et al., Immunotherapy for Alzheimer's disease. Proc Natl Acad Sci U S A, 2004. 101 Suppl 2: p. 14657-62. 4. Farrer, L.A., L.A. Cupples, J.L. Haines, et al., Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA, 1997. 278(16): p. 1349-56. 5. Andersen, K., L.J. Launer, M.E. Dewey, et al., Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. EURODEM Incidence Research Group. Neurology, 1999. 53(9): p. 1992-7. 6. Ballard, C., S. Gauthier, A. Corbett, et al., Alzheimer's disease. Lancet, 2011. 377(9770): p. 1019-31. 7. Sperling, R.A., P.S. Aisen, L.A. Beckett, et al., Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement, 2011. 7(3): p. 280-92. 8. Albert, M.S., S.T. DeKosky, D. Dickson, et al., The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement, 2011. 7(3): p. 270-9. 9. Larrieu, S., L. Letenneur, J.M. Orgogozo, et al., Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology, 2002. 59(10): p. 1594-9. 10. Gauthier, S., B. Reisberg, M. Zaudig, et al., Mild cognitive impairment. Lancet, 2006. 367(9518): p. 1262-70. 11. Honjo, K., R. van Reekum, and N.P. Verhoeff, Alzheimer's disease and infection: do infectious agents contribute to progression of Alzheimer's disease? Alzheimers Dement, 2009. 5(4): p. 348-60. 12. Gale, S.D., L.D. Erickson, B.L. Brown, et al., Interaction between Helicobacter pylori and latent toxoplasmosis and demographic variables on cognitive function in young to middle-aged adults. PLoS One, 2015. 10(1): p. e0116874. 13. Katan, M., Y.P. Moon, M.C. Paik, et al., Infectious burden and cognitive function: the Northern Manhattan Study. Neurology, 2013. 80(13): p. 1209-15. 14. Miklossy, J. and P.L. McGeer, Common mechanisms involved in Alzheimer's disease and type 2 diabetes: a key role of chronic bacterial infection and inflammation. Aging (Albany NY), 2016. 8(4): p. 575-88. 15. Grammas, P. and R. Ovase, Inflammatory factors are elevated in brain microvessels in Alzheimer's disease. Neurobiol Aging, 2001. 22(6): p. 837-42. 16. Heneka, M.T., M.J. Carson, J. El Khoury, et al., Neuroinflammation in Alzheimer's disease. Lancet Neurol, 2015. 14(4): p. 388-405. 17. Ringheim, G.E. and K. Conant, Neurodegenerative disease and the neuroimmune axis (Alzheimer's and Parkinson's disease, and viral infections). J Neuroimmunol, 2004. 147(1-2): p. 43-9. 18. Cover, T.L. and M.J. Blaser, Helicobacter pylori in health and disease. Gastroenterology, 2009. 136(6): p. 1863-73. 19. 鄭嘉琪, 臺灣五區域幽門螺旋桿菌血清流行病學研究及水中幽門螺旋桿菌之偵測, in 臨床醫學研究所2008, 臺灣大學. p. 1-48. 20. Lin, J.T., J.T. Wang, T.H. Wang, et al., Helicobacter pylori infection in a randomly selected population, healthy volunteers, and patients with gastric ulcer and gastric adenocarcinoma. A seroprevalence study in Taiwan. Scand J Gastroenterol, 1993. 28(12): p. 1067-72. 21. Shindler-Itskovitch, T., R. Ravona-Springer, A. Leibovitz, et al., A Systematic Review and Meta-Analysis of the Association between Helicobacterpylori Infection and Dementia. J Alzheimers Dis, 2016. 52(4): p. 1431-42. 22. Kountouras, J., M. Boziki, E. Gavalas, et al., Eradication of Helicobacter pylori may be beneficial in the management of Alzheimer's disease. J Neurol, 2009. 256(5): p. 758-67. 23. Kountouras, J., M. Boziki, E. Gavalas, et al., Five-year survival after Helicobacter pylori eradication in Alzheimer disease patients. Cogn Behav Neurol, 2010. 23(3): p. 199-204. 24. Chang, Y.P., G.F. Chiu, F.C. Kuo, et al., Eradication of Helicobacter pylori Is Associated with the Progression of Dementia: A Population-Based Study. Gastroenterol Res Pract, 2013. 2013: p. 175729. 25. Wang, X.L., J. Zeng, J. Feng, et al., Helicobacter pylori filtrate impairs spatial learning and memory in rats and increases beta-amyloid by enhancing expression of presenilin-2. Front Aging Neurosci, 2014. 6: p. 66. 26. Wang, X.L., J. Zeng, Y. Yang, et al., Helicobacter pylori filtrate induces Alzheimer-like tau hyperphosphorylation by activating glycogen synthase kinase-3beta. J Alzheimers Dis, 2015. 43(1): p. 153-65. 27. Baudron, C.R., L. Chambonnier, A. Buissionniere, et al., An Eighteen-Month Helicobacter Infection Does Not Induce Amyloid Plaques or Neuroinflammation in Brains of Wild Type C57BL/6J Mice. J Alzheimers Dis, 2015. 45(4): p. 1045-50. 28. Santarelli, L., M. Gabrielli, F. Cremonini, et al., Atrophic gastritis as a cause of hyperhomocysteinaemia. Aliment Pharmacol Ther, 2004. 19(1): p. 107-11. 29. Rasool, S., S. Abid, M.P. Iqbal, et al., Relationship between vitamin B12, folate and homocysteine levels and H. pylori infection in patients with functional dyspepsia: a cross-section study. BMC Res Notes, 2012. 5: p. 206. 30. Riggs, K.M., A. Spiro, 3rd, K. Tucker, et al., Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the Normative Aging Study. Am J Clin Nutr, 1996. 63(3): p. 306-14. 31. Kountouras, J., E. Gavalas, M. Boziki, et al., Helicobacter pylori may be involved in cognitive impairment and dementia development through induction of atrophic gastritis, vitamin B-12 folate deficiency, and hyperhomocysteinemia sequence. Am J Clin Nutr, 2007. 86(3): p. 805-6; author reply 806-7. 32. Seshadri, S., A. Beiser, J. Selhub, et al., Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med, 2002. 346(7): p. 476-83. 33. Kountouras, J., E. Gavalas, C. Zavos, et al., Alzheimer's disease and Helicobacter pylori infection: Defective immune regulation and apoptosis as proposed common links. Med Hypotheses, 2007. 68(2): p. 378-88. 34. Ge, R. and X. Sun, The in vivo functions of a histidine-rich protein Hpn in Helicobacter pylori: linking gastric and Alzheimer's diseases together? Med Hypotheses, 2011. 77(5): p. 788-90. 35. Kountouras, J., G. Deretzi, C. Zavos, et al., Association between Helicobacter pylori infection and acute inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol, 2005. 12(2): p. 139-43. 36. Kountouras, J., G. Deretzi, E. Gavalas, et al., A proposed role of human defensins in Helicobacter pylori-related neurodegenerative disorders. Med Hypotheses, 2014. 82(3): p. 368-73. 37. Berrett, A.N., S.D. Gale, L.D. Erickson, et al., Folate and Inflammatory Markers Moderate the Association Between Helicobacter pylori Exposure and Cognitive Function in US Adults. Helicobacter, 2016. 38. Beydoun, M.A., G.A. Dore, J.A. Canas, et al., Helicobacter pylori seropositivity's association with markers of iron, 1-carbon metabolism, and antioxidant status among US adults: a structural equations modeling approach. PLoS One, 2015. 10(3): p. e0121390. 39. Berrett, A.N., S.D. Gale, L.D. Erickson, et al., Helicobacter pylori moderates the association between 5-MTHF concentration and cognitive function in older adults. PLoS One, 2018. 13(1): p. e0190475. 40. Gunstad, J., L. Bausserman, R.H. Paul, et al., C-reactive protein, but not homocysteine, is related to cognitive dysfunction in older adults with cardiovascular disease. J Clin Neurosci, 2006. 13(5): p. 540-6. 41. McCully, K.S., Hyperhomocysteinemia, Suppressed Immunity, and Altered Oxidative Metabolism Caused by Pathogenic Microbes in Atherosclerosis and Dementia. Front Aging Neurosci, 2017. 9: p. 324. 42. Ravaglia, G., P. Forti, F. Maioli, et al., Plasma homocysteine and inflammation in elderly patients with cardiovascular disease and dementia. Exp Gerontol, 2004. 39(3): p. 443-50. 43. Malinow, M.R., A.G. Bostom, and R.M. Krauss, Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation, 1999. 99(1): p. 178-82. 44. Nilsson, K., L. Gustafson, and B. Hultberg, The plasma homocysteine concentration is better than that of serum methylmalonic acid as a marker for sociopsychological performance in a psychogeriatric population. Clin Chem, 2000. 46(5): p. 691-6. 45. van den Kommer, T.N., M.G. Dik, H.C. Comijs, et al., Homocysteine and inflammation: predictors of cognitive decline in older persons? Neurobiol Aging, 2010. 31(10): p. 1700-9. 46. Baron, R., I. Harpaz, A. Nemirovsky, et al., Immunity and neuronal repair in the progression of Alzheimer's disease: a brief overview. Exp Gerontol, 2007. 42(1-2): p. 64-9. 47. Plassman, B.L., J.W. Williams, Jr., J.R. Burke, et al., Systematic review: factors associated with risk for and possible prevention of cognitive decline in later life. Ann Intern Med, 2010. 153(3): p. 182-93. 48. Tsai, C.F., W.J. Lee, S.J. Wang, et al., Psychometrics of the Montreal Cognitive Assessment (MoCA) and its subscales: validation of the Taiwanese version of the MoCA and an item response theory analysis. Int Psychogeriatr, 2012. 24(4): p. 651-8. 49. Wang, C.S., M.C. Pai, P.L. Chen, et al., Montreal Cognitive Assessment and Mini-Mental State Examination performance in patients with mild-to-moderate dementia with Lewy bodies, Alzheimer's disease, and normal participants in Taiwan. Int Psychogeriatr, 2013. 25(11): p. 1839-48. 50. Nasreddine, Z.S., N.A. Phillips, V. Bedirian, et al., The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc, 2005. 53(4): p. 695-9. 51. Chang, Y.T., C.C. Chang, H.S. Lin, et al., Montreal cognitive assessment in assessing clinical severity and white matter hyperintensity in Alzheimer's disease with normal control comparison. Acta Neurol Taiwan, 2012. 21(2): p. 64-73. 52. Wechsler, D.A., Wechsler memory scale for adults, 3rd Ed. San Antonio, TX: The Psychological Corporation, 1997. 53. Bobko, P., P. L. Roth, and M.A. Buster, The Usefulness of Unit Weights in Creating Composite Scores: A Literature Review, Application to Content Validity, and Meta-Analysis. Vol. 10. 2007. 689-709. 54. Araujo, N.B., M.L. Barca, K. Engedal, et al., Verbal fluency in Alzheimer's disease, Parkinson's disease, and major depression. Clinics (Sao Paulo), 2011. 66(4): p. 623-7. 55. Whiteside, D.M., T. Kealey, M. Semla, et al., Verbal Fluency: Language or Executive Function Measure? Appl Neuropsychol Adult, 2016. 23(1): p. 29-34. 56. Bowden, S.C., V.M. Petrauskas, F.J. Bardenhagen, et al., Exploring the dimensionality of digit span. Assessment, 2013. 20(2): p. 188-98. 57. JO., K. and M. CW., Factor analysis : statistical methods and practical issues: Sage Publication, Inc. . 1978. 58. Craig, C.L., A.L. Marshall, M. Sjostrom, et al., International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc, 2003. 35(8): p. 1381-95. 59. Andresen, E.M., J.A. Malmgren, W.B. Carter, et al., Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale). Am J Prev Med, 1994. 10(2): p. 77-84. 60. Sheu, B.S., S.C. Shiesh, H.B. Yang, et al., Implications of Helicobacter pylori serological titer for the histological severity of antral gastritis. Endoscopy, 1997. 29(1): p. 27-30. 61. Ghebranious, N., L. Ivacic, J. Mallum, et al., Detection of ApoE E2, E3 and E4 alleles using MALDI-TOF mass spectrometry and the homogeneous mass-extend technology. Nucleic Acids Res, 2005. 33(17): p. e149. 62. Baron, R.M. and D.A. Kenny, The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol, 1986. 51(6): p. 1173-82. 63. Bu, X.L., X.Q. Yao, S.S. Jiao, et al., A study on the association between infectious burden and Alzheimer's disease. Eur J Neurol, 2015. 22(12): p. 1519-25. 64. Nagga, K., R. Rajani, E. Mardh, et al., Cobalamin, folate, methylmalonic acid, homocysteine, and gastritis markers in dementia. Dement Geriatr Cogn Disord, 2003. 16(4): p. 269-75. 65. Belleville, S., H. Chertkow, and S. Gauthier, Working memory and control of attention in persons with Alzheimer's disease and mild cognitive impairment. Neuropsychology, 2007. 21(4): p. 458-69. 66. Shallice, T. and P.W. Burgess, Deficits in strategy application following frontal lobe damage in man. Brain, 1991. 114 ( Pt 2): p. 727-41. 67. Alberoni, M., A. Baddeley, S.D. Sala, et al., Keeping track of a conversation: Impairments in Alzheimer's disease. International Journal of Geriatric Psychiatry, 1992. 7(9): p. 639-646. 68. Tu, M.C., C.P. Lo, C.F. Huang, et al., Visual Attention Performances and Related Cerebral Microstructural Integrity Among Subjects With Subjective Cognitive Decline and Mild Cognitive Impairment. Front Aging Neurosci, 2018. 10: p. 268. 69. Bracco, L., V. Bessi, S. Padiglioni, et al., Do cholinesterase inhibitors act primarily on attention deficit? A naturalistic study in Alzheimer's disease patients. J Alzheimers Dis, 2014. 40(3): p. 737-42. 70. Naftolin, F., C. Leranth, J. Perez, et al., Estrogen induces synaptic plasticity in adult primate neurons. Neuroendocrinology, 1993. 57(5): p. 935-9. 71. Toran-Allerand, C.D., R.C. Miranda, W.D. Bentham, et al., Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc Natl Acad Sci U S A, 1992. 89(10): p. 4668-72. 72. Bauer, J., U. Ganter, S. Strauss, et al., The participation of interleukin-6 in the pathogenesis of Alzheimer's disease. Res Immunol, 1992. 143(6): p. 650-7. 73. Jaffe, A.B., C.D. Toran-Allerand, P. Greengard, et al., Estrogen regulates metabolism of Alzheimer amyloid beta precursor protein. J Biol Chem, 1994. 269(18): p. 13065-8. 74. Mooradian, A.D., Antioxidant properties of steroids. J Steroid Biochem Mol Biol, 1993. 45(6): p. 509-11. 75. Brown, L.M., Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev, 2000. 22(2): p. 283-97. 76. Beydoun, M.A., H.A. Beydoun, M.R. Shroff, et al., Helicobacter pylori Seropositivity and Cognitive Performance Among US Adults: Evidence From a Large National Survey. Psychosom Med, 2013. 75(5): p. 486-96. 77. Jellinger, K.A., Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies. J Neural Transm (Vienna), 2018. 125(4): p. 615-650. 78. Ye, B.S., S.W. Seo, J.H. Kim, et al., Effects of amyloid and vascular markers on cognitive decline in subcortical vascular dementia. Neurology, 2015. 85(19): p. 1687-93. 79. Graham, N.L., T. Emery, and J.R. Hodges, Distinctive cognitive profiles in Alzheimer’s disease and subcortical vascular dementia. Journal of Neurology, Neurosurgery & Psychiatry, 2004. 75(1): p. 61-71. 80. Xu, Y., Q. Wang, Y. Liu, et al., Is Helicobacter pylori infection a critical risk factor for vascular dementia? Int J Neurosci, 2016. 126(10): p. 899-903. 81. Shindler-Itskovitch, T., G. Chodick, V. Shalev, et al., Helicobacter pylori infection and prevalence of stroke. Helicobacter, 2019. 24(1): p. e12553. 82. Shen, X., H. Yang, Y. Wu, et al., Meta-analysis: Association of Helicobacter pylori infection with Parkinson's diseases. Helicobacter, 2017. 22(5). 83. Huang, H.K., J.H. Wang, W.Y. Lei, et al., Helicobacter pylori infection is associated with an increased risk of Parkinson's disease: A population-based retrospective cohort study. Parkinsonism Relat Disord, 2018. 47: p. 26-31. 84. McColl, K.E., Clinical practice. Helicobacter pylori infection. N Engl J Med, 2010. 362(17): p. 1597-604. 85. Lee, J.H., N. Kim, J.I. Chung, et al., Long-term follow up of Helicobacter pylori IgG serology after eradication and reinfection rate of H. pylori in South Korea. Helicobacter, 2008. 13(4): p. 288-94. 86. Malaguarnera, M., R. Bella, G. Alagona, et al., Helicobacter pylori and Alzheimer's disease: a possible link. Eur J Intern Med, 2004. 15(6): p. 381-386. 87. Roubaud-Baudron, C., P. Krolak-Salmon, I. Quadrio, et al., Impact of chronic Helicobacter pylori infection on Alzheimer's disease: preliminary results. Neurobiol Aging, 2012. 33(5): p. 1009 e11-9. 88. Adriani, A., S. Fagoonee, C. De Angelis, et al., Helicobacter pylori infection and dementia: can actual data reinforce the hypothesis of a causal association? Panminerva Med, 2014. 56(3): p. 195-9. 89. Malfertheiner, P., P. Sipponen, M. Naumann, et al., Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol, 2005. 100(9): p. 2100-15. 90. Glupczynski, Y., F. Megraud, M. Lopez-Brea, et al., European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis, 2001. 20(11): p. 820-3. 91. Harthug, S., R. Jureen, S.C. Mohn, et al., The prevalence of faecal carriage of ampicillin-resistant and high-level gentamicin-resistant enterococci among inpatients at 10 major Norwegian hospitals. J Hosp Infect, 2002. 50(2): p. 145-54. 92. Perez Aldana, L., M. Kato, S. Nakagawa, et al., The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter, 2002. 7(5): p. 306-9. 93. Sjolund, M., K. Wreiber, D.I. Andersson, et al., Long-term persistence of resistant Enterococcus species after antibiotics to eradicate Helicobacter pylori. Ann Intern Med, 2003. 139(6): p. 483-7. 94. Adamsson, I., C.E. Nord, P. Lundquist, et al., Comparative effects of omeprazole, amoxycillin plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori-infected patients. J Antimicrob Chemother, 1999. 44(5): p. 629-40. 95. Blaser, M.J., Y. Chen, and J. Reibman, Does Helicobacter pylori protect against asthma and allergy? Gut, 2008. 57(5): p. 561-7. 96. Kyburz, A. and A. Muller, Helicobacter pylori and Extragastric Diseases. Curr Top Microbiol Immunol, 2017. 400: p. 325-347. 97. Kountouras, J., M. Tsolaki, E. Gavalas, et al., Relationship between Helicobacter pylori infection and Alzheimer disease. Neurology, 2006. 66(6): p. 938-40. 98. Kountouras, J., M. Tsolaki, M. Boziki, et al., Association between Helicobacter pylori infection and mild cognitive impairment. Eur J Neurol, 2007. 14(9): p. 976-82. 99. Petersen, R.C., G.E. Smith, S.C. Waring, et al., Mild cognitive impairment: clinical characterization and outcome. Arch Neurol, 1999. 56(3): p. 303-8. 100. Kountouras, J., M. Boziki, E. Gavalas, et al., Increased cerebrospinal fluid Helicobacter pylori antibody in Alzheimer's disease. Int J Neurosci, 2009. 119(6): p. 765-77. 101. Shiota, S., K. Murakami, A. Yoshiiwa, et al., The relationship between Helicobacter pylori infection and Alzheimer's disease in Japan. J Neurol, 2011. 258(8): p. 1460-3. 102. Roubaud Baudron, C., L. Letenneur, A. Langlais, et al., Does Helicobacter pylori infection increase incidence of dementia? The Personnes Agees QUID Study. J Am Geriatr Soc, 2013. 61(1): p. 74-8. 103. Huang, W.S., T.Y. Yang, W.C. Shen, et al., Association between Helicobacter pylori infection and dementia. J Clin Neurosci, 2014. 21(8): p. 1355-8. 104. Fani, L., F.J. Wolters, M.K. Ikram, et al., Helicobacter pylori and the risk of dementia: A population-based study. Alzheimers Dement, 2018. 105. Beydoun, M.A., H.A. Beydoun, M. Elbejjani, et al., Helicobacter pylori seropositivity and its association with incident all-cause and Alzheimer's disease dementia in large national surveys. Alzheimers Dement, 2018. 14(9): p. 1148-1158. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/handle/123456789/679 | - |
dc.description.abstract | 背景
許多文獻提出慢性幽門螺旋桿菌感染可能導致認知功能障礙。然而,之前的研究結果並不一致。在西元2016年,一個集合了7篇研究的統合分析顯示幽門螺旋桿菌感染和失智症有顯著相關性,其匯集勝算比(pooled odds ratio)為1.71。但是一篇最近發表的大型世代追蹤研究卻沒有顯示此關聯性。 材料與方法 本研究是橫斷性研究,招募了587位於2011及2013年間參加台大醫院老人健康檢查65歲以上之老人。我們使用酵素免疫法檢測血清中幽門螺旋桿菌免疫球蛋白G濃度,並使用各種神經精神測試來評估整體和特定領域的認知功能,再利用多變量線性回歸和邏輯斯回歸模型來評估血清幽門桿菌免疫球蛋白G濃度(IgG) 與認知功能障礙之間的關聯。 結果 與幽門螺旋桿菌免疫球蛋白G濃度的最低四分位數的老人(Q1)相比,最高四分位數(Q4)的長者其語言流暢度(蔬菜項目)(β係數= -0.24, 95%信賴區間= -0.45, -0.03; 勝算比= 1.53, 95 %信賴區間= 0.88, 2.66),專注功能領域(數字記憶跨度-正向)( β係數= -0.19, 95%信賴區間= -0.42, -0.04; 勝算比= 1.83, 95%信賴區間= 1.03-3.24)和專注功能因子(β係數= -0.20, 95%信賴區間= -0.37, -0.02; 勝算比= 2.67,95%信賴區間= 1.51, 4.73)的表現較差。整體認知功能和幽門螺旋桿菌免疫球蛋白G濃度沒有顯著的關聯。分層分析顯示,在男性中,血清幽門螺旋桿菌免疫球蛋白G濃度為最高四分位數的老人其語言流暢度(蔬菜項目)表現較差(β係數= -0.38, 95%信賴區間= -0.66, -0.09; 勝算比= 3.01, 95%信賴區間= 1.42, 6.38)。 結論 我們的研究結果顯示,較高的血清幽門螺旋桿菌免疫球蛋白G濃度與語言及專注功能的認知障礙風險有關聯。 公共衛生上的應用 本研究顯示根除幽門螺桿菌也許可以做為認知功能障礙的初段預防方法。我們使用血清學檢測評估幽門螺桿菌感染,此方法屬於非侵入檢查且價格較低廉,適用於社區老年族群的大規模篩查和檢測。 | zh_TW |
dc.description.abstract | Background/purpose: Helicobacter pylori (H. pylori) infection has been positively associated with cognitive impairment. However, previous studies have shown inconsistent findings. In 2016, one meta-analysis including 7 studies found a significant association between H. pylori infection and dementia with a pooled odds ratio of 1.71 but a recent large cohort study did not confirm these findings.
Material & Methods: This cross-sectional study included 587 elderly participants (age ≥ 65) from the annual elderly health checkup program at National Taiwan University Hospital from 2011 to 2013. H. pylori infection was assessed by a serology test of IgG using a commercial enzyme immunoassay (EIA). Both global and domain-specific cognition were assessed using various neuropsychological tests. Factor analysis, multivariable linear regression and logistic regression models were utilized to assess the association between the serum H. pylori IgG level and cognitive impairment. Results: Compared with the lowest quartile of H. pylori IgG (Q1), the highest quartile (Q4) was associated with lower performance on verbal fluency-vegetables [(β=-0.24, 95% confidence interval (CI)= -0.45, -0.03; odds ratio (OR) =1.53, 95% confidence interval (CI)= 0.88, 2.66)], attention domain [digit span-forward: β=-0.19, 95% confidence interval (CI) = -0.42, -0.04; odds ratio (OR) =1.83, 95% confidence interval (CI) = 1.03, 3.24], and attention factor (β=-0.20, 95% confidence interval (CI) = -0.37, -0.02; OR= 2.67, 95% CI = 1.51, 4.73). No significant association was observed for global cognition. Stratified analyses revealed that, among men, the highest quartile (Q4) of serum H. pylori IgG was associated with poor performance on verbal fluency-vegetables (β= -0.38, 95% CI=-0.66, -0.09; OR=3.01, 95% CI=1.42, 6.38). Conclusion: Our findings disclosed a positive association between serum H. pylori level and cognitive impairment of verbal fluency and attention function. Public health implication Our study provides important information for the primary prevention of cognitive impairment through the eradication of H. pylori. To assess H. pylori infection, we performed a serology test that is relatively non-invasive, inexpensive and suitable for mass screening and early detection of the high-risk group in the community dwelling elderly. | en |
dc.description.provenance | Made available in DSpace on 2021-05-11T04:56:14Z (GMT). No. of bitstreams: 1 ntu-108-D01849015-1.pdf: 4118947 bytes, checksum: 1219d34a195df55bf9dfee573432eb13 (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 口試委員審定書 ii
致謝 iii 縮寫表 iv 中文摘要 v Abstract vi Table of Contents viii List of Figures x List of Tables xi List of Appendices xii Chapter 1. Introduction 1 1.1 Dementia and mild cognitive impairment 1 1.2 Chronic infection and cognitive impairment 3 1.3 Chronic H. pylori infection and cognitive impairment 4 1.4 Chronic inflammatory markers, one carbon metabolism and cognitive impairment 6 1.5 Research gaps and study aims 8 Chapter 2. Materials and Methods 9 2.1 Study design and population 9 2.2 Cognitive assessment 10 2.3 Covariates 14 2.4 Laboratory assay 15 2.5 Statistical analyses 17 2.6 Mediation and moderation analyses 19 Chapter 3. Results 21 3.1 Characteristics of the study population 21 3.2 Identification of cognitive factors 22 3.3 Association between H. pylori IgG quartiles and cognitive function 23 3.4 Stratified analyses by selected covariates 24 3.5 Mediation analyses of factors involved in one carbon metabolism and inflammatory markers for the association between H. pylori infection and cognitive impairment 25 3.6 Moderation analysis of factors involved in one carbon metabolism and inflammatory markers for the association between H. pylori infection and cognitive impairment 26 Chapter 4. Discussion 27 4.1 Main findings 27 4.2. Sex difference for the association between H. pylori infection and cognitive function 29 4.3. Comparison with previous studies 30 4.4. Strengths 32 4.5. Limitations 33 4.6. Implications in public health 34 Chapter 5. Conclusion and future perspectives 35 References 67 Appendices 74 | |
dc.language.iso | en | |
dc.title | 慢性幽門桿菌感染和老人認知功能障礙之關聯研究 | zh_TW |
dc.title | Association between the Chronic Infection of Helicobacter pylori and Cognitive Impairment in the Elderly | en |
dc.date.schoolyear | 107-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 劉志銘(Jyh-Ming Liou),丘政民(Jeng-Min Chiou),陳人豪(Jen-Hau Chen),陳達夫(Ta-Fu Chen),施惟量(Wei-Liang Shih) | |
dc.subject.keyword | 幽門桿菌,感染,認知功能障礙,老人, | zh_TW |
dc.subject.keyword | Helicobacter pylori,Infection,Cognitive impairment,Elders, | en |
dc.relation.page | 83 | |
dc.identifier.doi | 10.6342/NTU201902522 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2019-08-12 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 流行病學與預防醫學研究所 | zh_TW |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf | 4.02 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。